6 completed. 6 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 1 | Completed 1 |
Follow lifitegrast: new trials by email Literature Review of lifitegrast trials Research Report on lifitegrast
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane - Dry Eye Disease | Phase 2 | Completed | Bausch & Lomb Incorporated | 443 | 2025-10-24 | 2026-07-14 |
| An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution) - Dry Eye | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 56 | 2021-09-09 | 2025-02-28 |
| A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3% - Dry Eye Disease | Phase 2 | Completed | Surface Ophthalmics, Inc. | 349 | 2021-01-11 | 2025-05-11 |
| A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease AGN-242428, AGN-231868, AGN-242428 Vehicle - Dry Eye Disease, Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | AbbVie | 292 | 2020-03-04 | 2025-05-20 |
| A Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE) Lifitegrast, Placebo - Dry Eye | Phase 2 | Completed | Shire | 230 | 2009-08-03 | 2021-08-09 |
| Efficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis Lifitegrast, Placebo - Allergic Conjunctivitis | Phase 2 | Completed | Shire | 60 | 2009-04-24 | 2021-06-11 |
Dry Eye Syndromes (5) · Conjunctivitis, Allergic (1)
Shire (2) · AbbVie (1) · Aldeyra Therapeutics, Inc. (1) · Bausch & Lomb Incorporated (1) · Surface Ophthalmics, Inc. (1)
United States (5) · Canada (1)